Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

Previously, Dr. Hefti was Senior Vice President of Neuroscience Research at Merck, Director of Neuroscience Research at Genentech, and a Professor at the University of Southern California and Associate Professor at the University of Miami.

"The recent failures of a gamma secretase inhibitor and the limited efficacy observed so far with non-selective amyloid beta immunotherapies indicates that industry may have been focused on suboptimal targets within the amyloid beta pathways," stated Dr. Hefti. "Our Merck colleagues successfully advanced anti-ADDL antibody therapeutics to a late pre-clinical development stage based on antibodies that we believe will allow Acumen to develop a best in class, disease modifying therapy for Alzheimer's disease."

William Goure, Ph.D., has been appointed Acumen's Chief Operating Officer, a position he formerly held.

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a development stage biotechnology company focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license rights to key patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merz Pharmaceuticals, GmbH for the development of certain small molecule therapeutics for Alzheimer's disease.


'/>"/>
SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 India’s ... business can potentially be worth up to a ... opportunity, the Indian government is taking serious action ... the process. , This presentation will examine:, ... regulations ,     Immediate and long term impacts ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... A new look at “big glass” and visionary ... highlight technical sessions at SPIE Photomask Technology 2013 ... year, the three-day event is the industry’s largest mask ... 100 technical presentations and numerous networking lunches and receptions. ... and photonics , the meeting will be held at ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
Breaking Biology Technology:Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Johnson & Johnson (NYSE: JNJ ) ... of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that ... is expected to operate as a stand-alone entity reporting ... Johnson & Johnson , Caring for the world, ...
... SUNNYVALE, Calif., Dec. 30 Accuray Incorporated,(Nasdaq: ARAY ... today,that its president and chief executive officer, Euan S. Thomson, ... Healthcare Conference in San,Francisco, on Wednesday, January 14, 2009 at ... A live webcast of the presentation will be available ...
... and PHILADELPHIA, Pennsylvania,December 29 Rosetta Genomics, ... molecular diagnostics, announced,today the introduction of its ... now commercially available through Rosetta Genomics CLIA-certified,lab ... To order the test, physicians may contact ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at 27th Annual JP Morgan Healthcare Conference 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5
(Date:6/18/2013)... -- Paris Air Show – Marvin Test Solutions ... leading provider of innovative test solutions for military ... this week at the Paris Air Show ... increasingly complex armament systems with longer lifecycles, industry ... solutions that address legacy system obsolescence. Marvin Test ...
(Date:6/18/2013)... the University of Calgary,s Faculty of Medicine have discovered ... from harmful bacteria. Platelets, a component of blood typically ... specific bacteria, and upon detection, seal it off from ... published in Nature Immunology this week, provide ... , "The science community has known that platelets do ...
(Date:6/18/2013)... Kingdom, the Energy Department,s National Renewable Energy Laboratory ... published a paper describing a novel cellulose-degrading enzyme ... , commonly known as the gribble. , ... relatively unique ability to produce their own enzymes ... the biomass they eat. New biomass-degrading enzymes from ...
Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2
... is available in French . A breakthrough ... and Denmark has uncovered a new gene that could lead ... a better understanding of how this widespread disease develops. ... diabetes, the new gene, called Insulin Receptor Substrate 1 (IRS1), doesn,t ...
... risk of bowel cancer has found that 50 percent ... implications. "This indicates that people have a significant ... have potentially life saving genetic testing," says co-lead author ... Centre for Women,s Health in Society. The population-based ...
... Taylor Chair of Chemistry Barry Dellinger was recently awarded a ... Health Sciences, or NIEHS, to support a Superfund Research Center ... health. It is the only center ever awarded by this ... school of public health. "This grant is the result of ...
Cached Biology News:Diabetes advance: Researchers find gene that causes resistance to insulin 2Diabetes advance: Researchers find gene that causes resistance to insulin 3Fear of insurance rejection deters potentially life saving genetic tests for bowel cancer 2LSU receives $3.6 million to fund center studying hazardous waste cleanup and health impacts 2
Request Info...
Sterile, individually wrapped, 4mm Cuvettes...
versican (H-56)...
... S1 Nuclease degrades single-stranded DNA and ... Double-stranded nucleic acids (DNA:DNA, DNA:RNA or ... with extremely high concentrations of enzyme ... remove single-stranded termini from double-stranded DNA ...
Biology Products: